Similar articles

• The ezetimibe Jonah: the trials and tribulations of an unlucky drug.

  Wierzbicki AS. Wierzbicki AS. Int J Clin Pract. 2011 Dec;65(12):1207-8. doi: 10.1111/j.1742-1241.2011.02789.x. Epub 2011 Sep 26. Int J Clin Pract. 2011. PMID: 21951808 No abstract available.
• Is intensive LDL-cholesterol lowering beneficial and safe?

  Cheung BM, Lam KS. Cheung BM, et al. Lancet. 2010 Nov 13;376(9753):1622-4. doi: 10.1016/S0140-6736(10)61545-0. Epub 2010 Nov 8. Lancet. 2010. PMID: 21067806 No abstract available.
• Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.

  McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P; IN-PRACTICE study. McCormack T, et al. Int J Clin Pract. 2010 Jul;64(8):1052-61. doi: 10.1111/j.1742-1241.2010.02429.x. Epub 2010 May 12. Int J Clin Pract. 2010. PMID: 20487050 Clinical Trial.
• [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk].

  Olsson AG. Olsson AG. Lakartidningen. 2011 Jun 1-14;108(22-23):1240-3. Lakartidningen. 2011. PMID: 21786498 Review. Swedish. No abstract available.
• [Statins in practice of the vascular surgeon and cardiologist].

  Pokrovskiĭ AV, Suntsov DS. Pokrovskiĭ AV, et al. Angiol Sosud Khir. 2009;15(2):123-7. Angiol Sosud Khir. 2009. PMID: 19806952 Review. Russian.